CureVac’s experimental COVID-19 vaccine triggered an immune response in humans, the German biotech firm said on Monday, putting it on track to start mass testing this year as the race to end the pandemic heats up.
“We are very encouraged by the interim Phase I data,” Chief Executive Officer Franz-Werner Haas said in a statement.
The biotech firm is using the so-called messenger RNA (mRNA) approach, the same as Moderna as well as BioNTech and its partner Pfizer, although they started mass testing on humans in late July.
CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated and trial results strongly supported the company’s plans to launch the final stage of testing involving about 30,000 participants before the end of the year.
CureVac – backed by German biotech investor Dietmar Hopp, the Gates Foundation and GlaxoSmithKline – said volunteers developed a level of neutralising antibodies on a par with people who had recovered from a serious case of COVID-19.
https://www.reuters.com/article/us-health-coronavirus-germany-curevac/curevacs-covid-19-vaccine-triggers-immune-response-in-phase-i-trial-idUSKBN27I1DBHELP US SPREAD GOOD NEWS!
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.